Cellectar Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cellectar Biosciences, Inc. (CLRB) on June 24, 2025. The report details a material corporate action involving the Company's capital structure.
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a corporate governance event.
Material Changes
On June 24, 2025, the Company effected a one-for-thirty reverse stock split of its common stock. This action was implemented by amending the Second Amended and Restated Certificate of Incorporation. Key details include:
- Split Ratio: One-for-thirty (1:30).
- Fractional Shares: No fractional shares were issued. Instead, fractional interests were sold by the transfer agent at prevailing market prices, with net proceeds distributed pro rata to affected holders.
- Securities Affected: Common Stock, par value $0.00001 per share, trading on The Nasdaq Capital Market.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It does not disclose new risks or contingencies beyond the standard incorporation of the Amendment text. The primary purpose is to notify the market of the reverse stock split and the amendment to the Articles of Incorporation.
Investor Verification Checklist
- Verify the post-split share count and adjusted share price on the Nasdaq Capital Market.
- Confirm the handling of fractional shares and the timing of cash distributions from the sale of fractional interests.
- Review the full text of the Amendment to the Second Amended and Restated Certificate of Incorporation (Exhibit 3.1) for any additional provisions.
- Check for any subsequent filings regarding the Company's compliance with Nasdaq listing standards following the split.